TORL BioTherapeutics LLC has closed a $96 million Series C financing. Proceeds will fund the ongoing clinical development of TORL-1-23, currently in a registrational Phase 2 study for platinum-resistant ovarian cancer. Updated results of TORL-1-23 will be presented at ESMO 2025. This financing aims to push pivotal studies toward key data readouts in 2027.
Who to call at TORL BioTherapeutics, and when
A new round usually means TORL BioTherapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day TORL BioTherapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TORL BioTherapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
TORL BioTherapeutics
Location
Culver City, California, United States
About
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TORL BioTherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Culver CityBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma